Watch this webinar to learn about tools & processes to help tailor COVID-19 therapies for special populations, including children and pregnant women
Considerations for Management of Clinical Trials and Regulatory Filing Strategy in Light of COVID-19
COVID-19 has the potential to negatively impact critical activities such as patient recruitment, patient safety and ensuring data integrity. Thus, clinical developers should review their planned regulatory filing strategies to determine if modifications are required. Attend this webinar to learn mitigation strategies and best practices that you can begin implementing now.
Clarus Therapeutics received FDA approval for an oral testosterone (T) replacement drug. This webinar will review how Phoenix NLME, population PK/PD M&S tool, and Trial Simulator supported this approval.
This webinar will explain how pricing has evolved for the rare disease drug market and best practices for supporting value-based pricing.
This webinar will explain how Certara expanded its PBPK Simcyp Simulator to incorporate an extensive dermal model— MPML MechDermA, a multi-phase, multi-dimensional dermal absorption model.
This webinar provided an update on the extensive recent additions to the mechanistic models for handling oral dosage forms available within the ADAM/M-ADAM framework.
This webinar explained how to conceptualize, optimize, and kick-off your mobile tool development process.
This webinar explained how the latest updates in the Simcyp Simulator v19, Certara’s physiologically-based pharmacokinetic (PBPK) modeling and simulation platform, will support developing safer, more effective medications faster.
This webinar addressed some of the challenges associated with pediatric drug development and the advantages (and limitations) that pediatric population PK modeling can provide.
This webinar showed how to use a time correction factor to establish a meaningful IVIVC for delayed release formulation drugs.